797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm

Abstract

In stage III melanoma, neoadjuvant (neoadj) IPI + NIVO induces high pathologic response rates (pRR 72-78%), which is associated with long-term RFS. Pts with a low baseline IFN-γ sign are less likely to respond (pRR 55%). Domatinostat (DOM), a class I histone deacetylase inhibitor, increased intratumoral T cell infiltration and the IFN-γ sign expression in melanoma. DONIMI tests neoadj combinations of NIVO ± IPI with DOM stratified according to the IFN-γ sign of baseline biopsies in stage IIIB-D nodal melanoma.